A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)

Trial Profile

A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs TSB 9-W1 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2016 Planned number of patients changed from 58 to 30.
    • 22 Apr 2016 Focus of the trial changed from TU+AR to AR as primary end point "Disease control rate" is removed. Phase of the trial changed from phase I/II to phase I and thus change in title.
    • 22 Apr 2016 Planned initiation date changed from 1 Nov 2014 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top